US Stock MarketDetailed Quotes

VIRX Viracta Therapeutics

Watchlist
  • 0.850
  • +0.046+5.71%
Trading May 15 14:59 ET
33.38MMarket Cap-690P/E (TTM)

About Viracta Therapeutics Company

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.

Company Profile

SymbolVIRX
Company NameViracta Therapeutics
Listing DateSep 27, 2005
Issue Price7.00
Founded1998
CEOMr. Mark Andrew Rothera
MarketNASDAQ
Employees40
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address2533 South Coast Highway 101,Suite 210
CityCardiff
ProvinceCalifornia
CountryUnited States of America
Zip Code92007
Phone1-858-400-8470
Websitehttp://www.viracta.com

Company Executives

  • Name
  • Position
  • Salary
  • Mark Andrew Rothera
  • Chief Executive Officer, President and Director
  • 1.46M
  • Dr. Darrel P. Cohen, M.D.,PhD
  • Chief Medical Officer
  • 756.73K
  • Dr. Melody Burcar
  • Interim Principal Financial Officer and Interim Principal Accounting Officer
  • --
  • Dr. Roger J. Pomerantz, F.A.C.P.,M.D.
  • Chairman of the Board
  • 210.27K
  • Dr. Ivor Royston, M.D.
  • Director
  • 90.76K
  • Dr. Sam Murphy, PhD
  • Independent Director
  • 95.76K
  • Dr. Flavia Borellini, PhD
  • Independent Director
  • 92.36K
  • Jane Chung
  • Independent Director
  • 90.76K
  • Dr. Jane F. Barlow, M.B.A.,M.D.,M.P.H.
  • Independent Director
  • 98.26K
  • Dr. Barry J. Simon, M.D.
  • Independent Director
  • 110.76K
  • Thomas E. Darcy
  • Independent Director
  • 113.26K
  • Dr. Stephen Rubino, M.B.A.,PhD
  • Independent Director
  • 108.26K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg